Action is needed to address the persisting under-representation of women in cardiovascular clinical trials, a new review shows. More than two decades after the FDA set up programs to ensure equal participation of women in clinical trials there are still serious gender imbalances in trials of therapies for ischaemic heart disease and heart failure, a ...
Six ways to fix the “alarming” gender bias in cardiovascular clinical trials
By Michael Woodhead
4 May 2018